Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis

C.S. Haworth, L. Sharples, V. Hughes, S.L. Elkin, M.E. Hodson, S.P. Conway, C. Etherington, J.S. Elborn, J. Rendall, E. Wheaton, E. Kadri, Jane Elliott, H.C. Barker, P.W.P. Bearcroft, T. Hlaing, J.E. Compston

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Background: The aim of this study was to assess the efficacy, tolerability and safety of risedronate in adults with CF. Methods: Patients with a lumbar spine (LS), total hip (TH) or femoral neck (FN) bone mineral density (BMD) Z-score of -1 or less were randomised to receive risedronate 35mg weekly or placebo, and calcium (1g)+vitamin D (800IU). Results: At baseline, BMD Z-scores in the risedronate (n = 17) and placebo (n = 19) groups were similar. By 24. months, 7/17 risedronate patients vs 0/19 placebo patients stopped the study medication due to bone pain. After 24. months treatment, the mean difference (95% CI) in change in LS, TH and FN BMD between the risedronate vs placebo groups was 4.3% (0.4, 8.2) p = 0.03; 4.0% (-0.5, 8.6) p = 0.08; and 2.4% (-3.5, 8.2) p =0.41. Conclusions: After two years treatment there was a significant increase in LS BMD with weekly risedronate compared to placebo.
Original languageEnglish
Pages (from-to)470-476
Number of pages7
JournalJournal of Cystic Fibrosis
Issue number6
Publication statusPublished - 01 Dec 2011


Dive into the research topics of 'Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis'. Together they form a unique fingerprint.

Cite this